SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
SEC Accession No. 0001193125-15-288160
Filing Date
2015-08-12
Accepted
2015-08-12 16:37:59
Documents
1
Group Members
ATHYRIUM CAPITAL HOLDINGS, LLCATHYRIUM CAPITAL MANAGEMENT, LPATHYRIUM OPPORTUNITIES ADVISERS LLCATHYRIUM OPPORTUNITIES ASSOCIATES GP LLCATHYRIUM OPPORTUNITIES ASSOCIATES LPATHYRIUM OPPORTUNITIES FUND (B) LPJEFFREY A. FERRELLNB ALTERNATIVES ADVISERS LLCNB

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 4 TO SCHEDULE 13D d68782dsc13da.htm SC 13D/A 212622
  Complete submission text file 0001193125-15-288160.txt   214807
Mailing Address 10 NORTH PARK PLACE SUITE 201 MORRISTOWN NJ 07960
Business Address 10 NORTH PARK PLACE SUITE 201 MORRISTOWN NJ 07960 (862) 260-8457
PERNIX THERAPEUTICS HOLDINGS, INC. (Subject) CIK: 0001024126 (see all company filings)

IRS No.: 330724736 | State of Incorp.: MD | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-50927 | Film No.: 151047443
SIC: 2834 Pharmaceutical Preparations

Mailing Address 605 THIRD AVENUE, 22ND FLOOR NEW YORK NY 10158
Business Address 605 THIRD AVENUE, 22ND FLOOR NEW YORK NY 10158 212.402.6925
Athyrium Opportunities Fund (A) LP (Filed by) CIK: 0001589714 (see all company filings)

IRS No.: 453564858 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A